-+ 0.00%
-+ 0.00%
-+ 0.00%

Larimar Therapeutics Q1 FY26 net loss widens to $29.61 million

PUBT·05/14/2026 20:22:20
Listen to the news
Larimar Therapeutics Q1 FY26 net loss widens to $29.61 million
  • Larimar Therapeutics posted a net loss of USD 29.61 million for the quarter ended March 31, 2026, versus USD 29.28 million a year earlier.
  • Operating loss narrowed to USD 31.12 million from USD 31.19 million, as total operating expenses edged down to USD 31.12 million.
  • Research and development expense slipped to USD 25.03 million while general and administrative costs climbed to USD 6.09 million.
  • Net cash used in operating activities widened to USD 44.61 million from USD 26.54 million, while cash, cash equivalents and marketable securities totaled USD 200.4 million as of March 31, 2026.
  • FDA granted Breakthrough Therapy Designation in February 2026; rolling BLA seeking accelerated approval planned to start in June 2026 with final modules in second half of 2026, targeting a U.S. launch in first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Larimar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-224087), on May 14, 2026, and is solely responsible for the information contained therein.